CD24FC

Summary

Cd24Fc (CHEMBL4297717) is a phase-3 clinical-stage unknown targeting SIGLEC10; indicated across 3 conditions including severe acute respiratory syndrome and neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Targets: 1 (SIGLEC10)
• Indications: 3 conditions
• Clinical trials: 5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297717
Name	CD24FC
Type	Unknown
Max phase	3

Also known as: Cd24fc, Cd24igg1fc, Efprezimod alfa, MK-7110, Saccovid, CD24FC

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
SIGLEC10	sialic acid binding Ig like lectin 10	Agonist		0.1%	Q96LC7

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): SIGLEC10.

Top Reactome pathways

3 total, by targets touching each:

Pathway	Targets	Genes
Adaptive Immune System	1	SIGLEC10
Immune System	1	SIGLEC10
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell	1	SIGLEC10

Dominant GO biological processes

GO term	Targets
adaptive immune response	1
cell adhesion	1
innate immune response	1
negative regulation of inflammatory response to wounding	1
immune system process	1

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
severe acute respiratory syndrome	3	MONDO:0005091	MONDO:0100096
neoplasm	1	MONDO:0005070	EFO:0000616
metastatic melanoma	1	MONDO:0005191	EFO:0002617

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE3	2
PHASE2	1
PHASE1/PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04095858	PHASE3	TERMINATED	Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005)
NCT04317040	PHASE3	COMPLETED	Efprezimod Alfa (CD24Fc, MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007)
NCT02663622	PHASE2	COMPLETED	Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002)
NCT04060407	PHASE1/PHASE2	WITHDRAWN	CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI)
NCT02650895	PHASE1	COMPLETED	Safety Study of Efprezimod Alfa (CD24Fc, MK-7110) When Administered Intravenously in Healthy Adult Subjects (MK-7110-001)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).